No products in the cart.
Brolucizumab Injection (Beovu) 27.6mg/0.23ml – Factory low price wholesale
$2.00
Beovu (Brolucizumab Injection) is supplied in a 0.23ml single-dose vial containing 27.6mg of active ingredient. Manufactured by Alcon-Couvreur N.V. and NMPA-approved under SJ20250019. Intended for non-clinical research use only.?For wholesale prices, other specifications and uses, please consult our staff?
Description
Brolucizumab is a humanized single-chain antibody fragment (scFv) targeting vascular endothelial growth factor A (VEGF-A). It is used in ophthalmological research to study mechanisms of wet age-related macular degeneration (wet AMD) and retinal vascular permeability.
Beovu delivers high molar concentration of anti-VEGF activity in a compact 27.6mg/0.23ml dosage form, enabling researchers to model retinal neovascularization, angiogenesis inhibition, and anti-VEGF pathways in both in vitro and in vivo settings.
?? This product is strictly intended for laboratory research use and is not approved for human or veterinary administration.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Brolucizumab Injection (Beovu) |
| Generic Name | Brolucizumab |
| CAS Number | 1612181-62-6 |
| Molecular Formula | Not applicable (monoclonal antibody fragment) |
| Molecular Weight | ~26 kDa |
| Dosage Form | Injection (lyophilized or liquid vial) |
| Strength | 27.6mg in 0.23ml |
| Quantity | 1 vial per box |
| Approval Number | SJ20250019 (China NMPA) |
| Product Code | 86978679002796 |
| Barcode | 86978679002796 |
| Manufacturer | Alcon-Couvreur N.V. (Belgium) |
| Intended Use | For laboratory research only |
| Storage | Store refrigerated at 2–8°C; do not freeze or shake |
Mechanism & Research Applications
Brolucizumab binds VEGF-A with high affinity, preventing interaction with VEGF receptors on endothelial cells, thereby suppressing angiogenesis and vascular leakage. It enables researchers to investigate:
Pathogenesis and treatment of wet age-related macular degeneration (wet AMD)
Experimental retinal angiogenesis models
Comparative efficacy of anti-VEGF agents
VEGF pathway inhibition and downstream signaling
Ocular pharmacokinetics of antibody fragments
Observed Effects in Research Models
In preclinical studies, Brolucizumab has shown:
Potent inhibition of neovascularization
Reduction in retinal thickness and fluid accumulation
Minimal systemic exposure due to small molecular size
Transient inflammation in animal eye models (dose-dependent)
Appropriate research protocols and animal care guidelines should be followed.
Safety & Handling
Use Restriction: Laboratory research use only.
Personal Protective Equipment: Gloves, goggles, lab coat
Storage: Refrigerate (2–8°C); avoid freezing
Disposal: Dispose of biological waste per local biosafety guidelines
Research Use Disclaimer
This product is strictly intended for laboratory research use only. It is not for clinical, therapeutic, diagnostic, or veterinary use. Misuse may result in legal or health risks. Always follow institutional biosafety and handling protocols.
Additional information
| Weight | 1 kg |
|---|---|
| Dimensions | 26 × 23 × 26 cm |
1 review for Brolucizumab Injection (Beovu) 27.6mg/0.23ml – Factory low price wholesale
Q1: Is Beovu Injection suitable for clinical or therapeutic use?
No, this product is for experimental use only. It is not approved for diagnostic, clinical, or therapeutic purposes.
Q2: Can I order this product in bulk quantities?
Yes, we support both wholesale and retail distribution. Please contact us for bulk pricing and logistics.
Q3: Do you provide COA and SDS documentation?
Yes, both the Certificate of Analysis (COA) and Safety Data Sheet (SDS) are available upon request for institutional buyers.
Q4: What research models commonly use Brolucizumab Injection?
It is frequently used in wet AMD animal models, anti-VEGF comparative research, and in vitro angiogenesis inhibition studies.
Q5: What makes Brolucizumab Injection (Beovu) unique among anti-VEGF agents?
Unlike larger monoclonal antibodies, Brolucizumab’s single-chain structure allows for higher molar dosing and deeper retinal penetration, making it ideal for VEGF-inhibition research and wet AMD studies.
Related products
Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only
Tirzepatide Injection (MOUNJARO) contains 40mg (4 doses of 10mg/0.6ml) per vial. Manufactured by Eli Lilly Italia S.p.A. Approved in China (HJ20255004). Intended for laboratory research only. Wholesale and retail supported.?For wholesale prices, other specifications and uses, please consult our staff? $1.00Linagliptin Tablets
High-purity Linagliptin 5mg tablets, 7count bottle packaging by Yangtze River Pharmaceutical Group – Shanghai Henley Pharma. Ideal for DPP4 inhibitor research into Type2 diabetes mechanisms, incretin pathways, and metabolic regulation.
$2.00
For laboratory research only – Not for human consumption or therapeutic use.Empagliflozin Tablets 10mg (Koltangen) – For Research Use Only
Empagliflozin Tablets (10mg) for research use only. Used in experimental studies on SGLT2 inhibition, glucose excretion, and type 2 diabetes models. Manufactured by Sichuan Kelun Pharmaceutical Co., Ltd.?For wholesale prices, other specifications and uses, please consult our staff?
$1.00Pioglitazone Hydrochloride Tablets (Aiting) 15mg – For Laboratory Research Use Only
Pioglitazone Hydrochloride Tablets (Aiting) contain 15mg of active compound per tablet. Supplied as 14 tablets (2 blister packs). Manufactured by Beijing Taiyang Pharmaceutical under NMPA approval H20040267. Suitable for lab research in glucose metabolism and insulin signaling.?For wholesale prices, other specifications and uses, please consult our staff?
$1.20
slw –
Thanks